Nef gene evolution from a single transmitted strain in acute SIV infection
© Bimber et al; licensee BioMed Central Ltd. 2009
Received: 29 January 2009
Accepted: 08 June 2009
Published: 08 June 2009
The acute phase of immunodeficiency virus infection plays a crucial role in determining steady-state virus load and subsequent progression of disease in both humans and nonhuman primates. The acute period is also the time when vaccine-mediated effects on host immunity are likely to exert their major effects on virus infection. Recently we developed a Monte-Carlo (MC) simulation with mathematical analysis of viral evolution during primary HIV-1 infection that enables classification of new HIV-1 infections originating from multiple versus single transmitted viral strains and the estimation of time elapsed following infection.
A total of 322 SIV nef SIV sequences, collected during the first 3 weeks following experimental infection of two rhesus macaques with the SIVmac239 clone, were analyzed and found to display a comparable level of genetic diversity, 0.015% to 0.052%, with that of env sequences from acute HIV-1 infection, 0.005% to 0.127%. We confirmed that the acute HIV-1 infection model correctly identified the experimental SIV infections in rhesus macaques as "homogenous" infections, initiated by a single founder strain. The consensus sequence of the sampled strains corresponded to the transmitted sequence as the model predicted. However, measured sequential decrease in diversity at day 7, 11, and 18 post infection violated the model assumption, neutral evolution without any selection.
While nef gene evolution over the first 3 weeks of SIV infection originating from a single transmitted strain showed a comparable rate of sequence evolution to that observed during acute HIV-1 infection, a purifying selection for the founder nef gene was observed during the early phase of experimental infection of a nonhuman primate.
Genetic evolution in the primary phase of HIV-1 infection has been characterized by single genome amplification and nested polymerase chain reaction (PCR) of HIV-1 genes in parallel with mathematical/computational modeling [1–3]. Major goals of such analyses include the characterization of the transmitted strains, estimating the timing of infection based on the level of sequence diversity, and distinguishing between single virus strain/variant infections (referred to hereafter as "homogenous" infection) versus two or more virus strains/variants infections (referred to hereafter as "heterogenous" infection). Heterogeneous infection is associated with faster sequence diversification and accelerated disease progression due to the rapid emergence of virus variants with enhanced replicative fitness [4–7].
To quantitatively assess whether HIV-1 infections were initiated by single or multiple viral strains, we recently developed a mathematical model and Monte-Carlo (MC) simulation model of HIV-1 evolution early in infection and applied this to the analysis of 102 individuals with acute HIV-1 infection . Further, in cases of single strain (homogeneous) infections, the model provided a theoretical basis for identifying early founder (possibly transmitted) env genes.
In this study, we tested the validity of our primary HIV-1 infection model using a non-human primate (NHP) model for HIV-1/AIDS. This model has played a key role in the development of candidate HIV-1 vaccines, and provided critical insights into disease pathogenesis [8–10]. Studies in the macaque/simian immunodeficiency virus (SIV) model have contributed to our understanding of the close association between the extent of virus replication during the acute phase of infection and the subsequent virus set point and disease course  as reported in HIV-1 infections [12–14]. Genetic evolution during SIV infection has been well documented in comparison with the evolution of HIV-1 population [15–18].
We examined evolution of the viral nef genes from a single transmitted strain. Nef, a small accessory protein, was selected because the virus can tolerate significant variability in the nef protein, as evidenced by high levels of polymorphism longitudinally throughout infection and at the population level [19–22]. We sequenced full-length nef genes longitudinally during the very early phase of SIV infection using the method of single genome amplification (SGA). The SGA method more accurately represents HIV-1 quasispecies when compared to conventional PCR amplification [1, 23, 24]. We showed that our sequence evolution model correctly classified the experimental SIV infections as homogeneous infections. As predicted by the model, the consensus sequence of the sampled strains from these homogeneous infections corresponded to the transmitted sequence. However, our systematic evaluation showed that a sequential decrease of the diversity within the first 3 weeks of infection was associated with a purifying selection for the transmitted sequence (and was not a consequence of the limited sample size in our analysis).
Longitudinal nucleotide and amino acid mutations
Dynamics of divergence, diversity, variance, maximum HD, and sequence identity
Animal Information and analysis using the acute HIV-1 infection model.
viral load (copies/ml)
Number of Sampled Sequences
χ2goodness of fit P value
The maximum HD of r98018 at day 21 is 5 due to the presence of a strain with 3 base substitutions from the founder strain. All three of these mutations are G to A hypermutation with APOBEC3G/F signatures [25–27], although the signatures were not found to be statistically significant (p > 0.05 from a Fisher exact test, Hypermut tool http://www.hiv.lanl.gov). Nonetheless, we tentatively attribute the deviation from the prediction generated by our model to these putative APOBEC3G/F signatures. The rate of virus sequence evolution in animal r00065 was slower than in animal r98018 – even though the virus replication rate (virus load) in animal r00065 was higher than that for animal r98018.
Single Variant (Homogeneous) Infection with Neutral Evolution
Estimating Days since Infection: Poisson Fit
where . Here t is days post infection, ε is the HIV-1 single replication cycle error rate per base, N B is the number of bases of sampled genes, and R0 is the basic reproductive ratio.
We used a Maximum Likelihood method to fit a Poisson distribution to the observed data, and then assessed the goodness of fit through a Chi-Square statistic. Table 1 summarizes the estimated days since infection obtained from the Poisson fit using the relationship between mean of Poisson distribution, λ0 and days post infection, t in Eq. (2), along with 95% CIs obtained by bootstrapping the HD0 distribution 105 times. All of the 7 samples yielded a goodness-of-fit p-value of greater than 0.5, suggesting that measured HD0 statistically follows a Poisson distribution. In this goodness of fit test the null hypothesis was that the two distributions tested were statistically the same, hence a low p-value would yield rejection of the null hypothesis. Analysis of all the sequence samples showed that the actual number of days elapsed following infection for the sequence samples fell within the 95% CIs of estimated days post infection by a Poisson fit to the HD0 distribution (Table 1). However, as we expected from the observed decrease in divergence and the increase in sequence identity as infection progresses, the correlation coefficient between actual days since infection and the estimated days post infection (based on the Poisson fit for animal r00065) was -0.91. The correlation coefficient for animal r98018 was 0.47.
The present study was undertaken to explore the applicability of a recently developed model for primary HIV-1 infection, to the analysis of acute SIV infection in rhesus macaques . The level of measured diversity ranged from 0.015% to 0.052% during primary SIV infection, before set point, which is comparable to the range of measured diversity, 0.005% to 0.127%, from 68 single strain infected patients at the primary stage of HIV-1 infection . Analysis of the SIV nef sequences showed that the MC simulation model was able to successfully classify 7 sequence samples, from two animals during the first 3 weeks following experimental infection of two rhesus macaques with SIVmac239, as homogeneous infection. We also confirmed that the consensus virus sequence in these animals was identical to the transmitted nef sequence of the infecting SIVmac239.
We observed an unexpected decline in the divergence and the diversity from animal r00065 at an early point following infection. We first hypothesized that the serial decline in the divergence might be due to fluctuations arising from the limited sample size, 31–50 sequences per time point. To address this concern, we performed a second simulation, starting with the actually sampled 41 nef genes obtained at day 7 from animal r00065 (which showed the divergence of 0.018%). The MC simulation was performed with the assumption of neutral evolution, and 31 sequences were sampled at day 18. The measured 95% CIs of the divergence from such 1000 simulations provided the basis for the rejection of the null hypothesis (neutral evolution without selection), implying a preferential selection process for the founder strain. We conclude that the decrease in the divergence observed in animal r00065 is reflective of a purifying selection rather than a stochastic effect due to small sample size. We speculate that the purifying selection can be explained as a result of either: (i) lower fitness of the emerging mutant viruses relative to the founder virus, or (ii) selective loss of mutant sequences due to linked, unfavorable changes elsewhere in the genome (i.e., the phenomenon of hitchhiking [29, 30]). The roles of Nef in viral fitness, such as promoting viral replication and infectivity and interfering T cell activation, have been well documented [31–33].
We observed that rapid viral replication kinetics were not necessarily associated with a greater rate of sequence evolution. Animal r00065 displayed a greater level of viral replication in comparison to animal r98018 while less diversification of nef genes was observed in animal r00065. We interrogated the relationship between HIV-1 sequence diversity and viral load from 28 subjects with homogeneous HIV-1 infection in Fiebig stage II, where viral RNA and p24 antigens are positive without detectable HIV-1 serum antibodies . We observed little correlation between plasma viral load and diversity (σ2 = 0.18) in HIV-1 acute infection.
Disconnect between the replication rate and the rate of evolution during early SIV and HIV infections may be partly explained by the unusual small effective population size, which has been estimated ranging from 103 to 104 [35–38]. The effective population size is defined from the process of transforming an actual, census population into a neutral, constant size population with non-overlapping generations. The difference between the effective population size and the real size can arise from many factors such as varying population size, purifying or diversifying selection and the existence of subpopulation. These factors should be associated with low level of correlation between viral load and the level of diversity in acute HIV-1 and SIV infections.
Another aspect we may consider is that low level of correlation might be explained within our model scheme where the reproductive ratio and the generation time are set as independent parameters. Viral sequence diversity is influenced more strongly by generation time and to much lesser extent by the reproductive ratio. Hence for a given viral generation time, if the reproductive ratio changes significantly, the ramp-up slope of infected cell varies accordingly while the rate of sequence diversification remains relatively stable, implying little correlation between the rate of evolution and the rate of replication. For instance, our calculation from the asynchronous infection model study shows that when we change the basic reproductive ratio from 6 to 12, the ramp-up slope of infected cells increases 45% but the slope of diversity increases only 6%. With the assumption that the basic reproductive ratio varies considerably among acute HIV-1 subjects, for example by the level of activated CD4 T cell at the transmission, we may observe a great level of variation in the viral load but less in the sequence diversity. Under this circumstance, a minor correlation can be detected at the population level with another factor for dampening the correlation, fluctuations arising from the limited sample size of genes.
An important caveat to the work reported here is that a limited number of clones were examined at specific time points in only 2 SIV infected animals. SGA sequencing is resource-intensive, precluding the use of more animals and time points in this study. In the future, next-generation pyrosequencing technologies  may facilitate the examination of far greater numbers of SIV sequences with economy that is impossible to achieve with Sanger-based sequencing. We expect that the acute infection model will be refined and improved as additional sequences become available.
This study verifies the robust nature of our MC simulation model for primary HIV-1 infection, and shows that it can be successfully applied to the analysis of acute SIV infection in rhesus macaques. The model predicted the level of SIV sequence diversification during the acute phase of SIVmac239 infection in two rhesus macaques, and it correctly identified "homogenous" virus transmission in this model system. SIV acute sequence samples confirmed that the consensus sequence of each sample was indeed the transmitted strain. Finally, a sequential decrease in viral diversity was observed during the first 3 weeks of infection in one macaque, and was found to be due to a purifying selection for the transmitted sequence.
Animals and SIVmac239 challenge
Two rhesus macaques were experimentally infected with the clonal SIV isolate SIVmac239, derived from a molecular clone . The SIVmac239 inoculum was sequenced by non limiting dilution PCR. The sequence of the infecting strain was identical to the clone from which it was derived with potential small errors during in vitro amplification. We have indicated the limitation in the revised manuscript. However, we note that our method is the best way for obtaining the clonal nature of the infecting inoculum as far as we can. Animal r00065 (r65) was infected with 100 TCID50 SIVmac239 by intravenous injection. Animal r00098 (r98) was infected by intrarectal inoculation with 10 MID50 SIVmac239. Viral RNA was isolated from frozen plasma samples from animal r00065 collected at days 4, 7, 11, and 18 following virus infection. From animal r00098, viral RNA was isolated from frozen plasma samples collected at days 4, 7, 21 during infection. Virally-infected animals were cared for according to the regulations of the University of Wisconsin Institutional Animal Care and Use Committee, and the NIH.
Viral RNA isolation and cDNA synthesis
Viral RNA was isolated from each animal at defined time points following infection. Cell-free plasma was prepared from EDTA anticoagulated whole blood by ficoll density gradient centrifugation. Viral RNA isolation was performed using the QIAamp MinElute Virus Spin Kit (QIAGEN, Valencia, CA) according to the manufacturer's instructions. Single strand cDNA was generated using oligo dT primers and the Superscript III reverse transcription kit (Invitrogen, Carlsbad, California, USA) according to the manufacturer's instructions.
Limiting Dilution and nested PCR
cDNA template was diluted to ~1 viral genome per microliter. The dilution factor necessary to achieve single viral genomes was defined as the template dilution for which only 30% of reactions produced a product. According to a Poisson distribution, the cDNA dilution that yields PCR products in no more than 30% of wells contains one amplifiable cDNA template per positive PCR more than 80% of the time. This was empirically determined using a dilution series and varied between samples and cDNA preps. The dilution series and PCR reactions were set up using a QIAGEN BR3000 liquid handling robot (QIAGEN, Valencia, CA). All PCR reactions used Phusion High-Fidelity polymerase (Finnzymes, Espoo, Finland). A nested PCR approach was used for all amplifications. The following primers designed to amplify a region of the viral Nef gene were used for the first round of PCR: 5'-CAAAGAAGGAGACGGTGGAG-3' and 5'-CATCAAGAAAGTGGGCGTTC-3'. Second round PCR was conducted using 2 ul of the first round PCR product and the following internal primers were used for nested PCR: 5'-TCAGCAACTGCAGAACCTTG-3' and 5'-CGTAACATCCCCTTGTGGAA-3'. For all PCR reactions, the following conditions were used: 98C for 30 s, 30 cycles of: 98C for 5 s, 63C for 1 s and 72C for 10 s, followed by 72C for 5 min. PCR products were run on a 1.5% agaroe gel. PCR products were purified using the Chargeswitch kit (Invitrogen, Carlsbad, Calfornia, USA) according to the manufacturer's instructions. Samples were bi-directionally sequenced susing ET-terminator chemistry on an Applied Biosystems 3730 Sequencer (Applied Biosystems, Foster City, California, USA) and the internal primers described above. DNA sequence alignments were performed using CodonCode Aligner version 2.0 (CodonCode Corporation, Dedham, Massachusetts, USA).
Modeling Sequence Evolution in Primary HIV-1/SIV Infection
The details of our model for characterizing sequence evolution in acute HIV-1 infection will be described by Lee et al. (HY Lee, EE Giorgi, BF Keele, B Gaschen, GS Athreya, JF Salazar-Gonzalez, KT Pham, PA Geopfert, JM Kilby, MS Saag, EL Delwart, MP Busch, BH Hahn, GM Shaw, BT Korber, T Bhattacharya, and AS Perelson, Modeling Sequence Evolution in Acute HIV-1 Infection, submitted for publication). We provide here an overview of the salient features of the model and its underlying assumptions. After transmission we assume that a systematic infection starts with a single infected cell in a new host. The number of secondary infections caused by one infected cell placed in a population of cells fully susceptible to infection is called the basic reproductive number, R0. The available data in humans infected with HIV-1 and in monkeys infected with SIV and SHIV show that virus grows exponentially until a viral load peak is attained a few weeks after infection [41–43]. Following the peak, viral levels decline and establish a set-point. At the set-point each infected cell, on average, successfully infects one other cell during its lifetime.
We assumed a homogeneous infection in which the virus grows exponentially with no selection pressure, no recombination, and a constant mutation rate across positions and across lineages. Cell infections occur randomly by the viruses released from an infected cell. Viral production starts on average about 24 hours after a cell is initially infected [44, 45], and most likely continues until cell death. While each of the R0 infections could occur at different times, we took a first step in assessing the role of asynchrony by assuming the infections occur at two different times. The average time to new infection defines the viral generation time, τ. Each new infection entails a single round of reverse transcription introducing errors in the proviral DNAs with the number of mutations given by the Binomial distribution, Binom(n; N B , ε), where n is the number of new base substitutions. Binomial distribution implies that base substitutions occur independently with the probability of ε at each site of SIV genome with the length N B in each reverse transcription cycle. The Monte-Carlo model explicitly emulates all the new infection procedures with mutations, tracking the population of proviral nef genes of the infected cells by introducing base substitutions as infection propagates in a new host.
In Ref. , we determined that the MC simulation and the mathematical model showed a good agreement with the level of sequence diversity sampled from acute HIV-1 subjects presumably infected with a single variant. Based on the prediction made by the model, the group of identical sequences, usually the consensus sequence of sampled strains, was presumed to be the initial founder strain established by the systematic infection in each host. The parameters used in the acute HIV-1 model were: i) the average generation time of productively infected cells, defined as the average time interval between the infection of a target cell and the subsequent infection of new cells by progeny virions, estimated as 2 days , ii) HIV-1 single cycle forward mutation rate, estimated as ε = 2.16 × 10-5 per site per cycle , and iii) the basic reproductive ratio, defined as the number of newly infected cells that arise from any one infected cell when almost all cells are uninfected, estimated as R0 = 6. In the asynchronous infection model, the first time at which a newly infected cell infects other cells, τ, is chosen as 1.5 days. The length of nef gene, N B , we simulated is 792. We used these parameter values to analyze our data set. For example, calculated R0 values during primary SIV infection from viral ramp-up slope ranged from 2.2 to 68 , which justifies the choice of R0 = 6. Improvement of the model requires more accurate estimations for these basic parameters during SIV early infection.
The mutation rate, ε, and the generation time, τ, control the rate of increase in divergence and hence diversity. The larger the mutation rate, the faster the genomes mutate, hence the steeper the growth in diversity. The greater the generation time, the slower the genomes diversify, hence the smaller the growth in diversity. The slope of diversification is approximately proportional to ε/τ. On the other hand, R0 mainly controls the growth in the infected cell population size. As the viral population grows, the number of cells one infected cell infects decreases due to the fact that fewer cells are available for infection. The basic reproductive ratio, R0, affects the rate of evolution in a relatively minor way. Low values (e.g. 2 ≤ R0 ≤ 4), slow down the growth in the infected cell population, thus affecting the speed of evolution. For example, from R0 = 6 to R0 = 2 there is a 15.9% increase in the slope of diversity. On the other hand, for R0 ≥ 6, the dependence of the rate of diversification on R0is reduced. The slope of diversity increases by 5.5% as we increase R0 from 6 to 10. The dynamics of diversity do not depend on the number of initial infected cells.
Once we sample a finite number of sequences from the MC simulation at a given time, we first measure the Hamming distance (HD0) between each sampled sequence and the founder sequence and the Hamming distance (HD) between sequences sampled at the same time. Here Hamming distance is the number of base substitutions between two sequences. Based on the calculated HD0 and HD, we define the basic measurements for quantifying the evolution of HIV-1 sequence populations. Divergence is defined as the average HD0 per base from the initial founder strain; diversity is defined as the average intersequence Hamming distance per base among sequence pairs at a given time; variance is defined as the variance of the intersequence per base HD distribution; maximum HD is defined as the measured maximum HD between all sequence pairs sampled, and sequence identity is defined as the proportion of sequences identical to the founder strain. Both the MC simulation and mathematical calculation showed that divergence, diversity, and variance increase linearly as a function of time and sequence identity decays exponentially as a function of time [Fig. 2]. These behaviours are characteristics of neutral evolution, characterized as Poisson distribution and star-phylogeny topology. It has been shown that the distribution of pairwise genetic distances is an approximate Poisson in the evolution of mitochondrial DNA . To address the issue of the finite size of samples, we repeated MC simulations sampling a finite number of nef genes at a given time and computed 95% CIs for each quantity. Then we examined whether the measurement of SIV nef gene samples was compatible with the model prediction or not. To infer the number of days elapsed since infection based on sampled strains, first we fit the Poisson distribution to the observed distribution of Hamming distances between sampled nef genes and the transmitted nef gene; we then determined the mean of the Poisson distribution and calculated days post infection using Eq. (2).
A key property of the Poisson distribution arising from neutral evolution without selection and recombination is that the level of diversity is comparable to that of variance. We used this property to examine whether sampled strains had evolved from a single founder strain or not. In each MC run, we obtained the values of diversity and variance from the sampled sequences with a given sample size at each time and located those values in the plane of diversity and variance. By repeating MC simulations, we collected all the values of diversity and variance and computed 95% CIs in the plane of diversity and variance. The computed 95% CIs form a conical region within which diversity and variance of the sampled sequences from the animal with homogeneous infection (i.e. infections with a single founder strain without any selection pressure or recombination) are expected to be located [Figure 5]. As we sample more, the conical region becomes smaller [Figure 5]. Another requirement for homogeneous infection is that the sequence diversity should be less than the upper limit of the 95% CIs of the diversity at a given time following infection with a single virus strain.
We thank B. T. Korber, B. F. Keele, T. Bhattacharya, and A. S. Perelson for critical reading and comments and M. Draheim for technical support. This publication was supported by NIAID/NIH grant AI083115, NIH grant AI049781, NCRR/NIH grant P51 RR000167, Research Facilities Improvement Program grant numbers RR15459-01 and RR020141-01, University of Rochester Developmental Center for AIDS research (NIH P30AI078498), and NIH P01 AI056356.
- Salazar-Gonzalez JF, Bailes E, Pham KT, Salazar MG, Guffey MB, Keele BF, Derdeyn CA, Farmer P, Hunter E, Allen S, et al: Deciphering Human Immunodeficiency Virus Type 1 Transmission and Early Envelope Diversification by Single Genome Amplification and Sequencing. J Virol. 2008, 82: 3952-70. 10.1128/JVI.02660-07.PubMed CentralView ArticlePubMed
- Keele BF, Salazar-Gonzalez JF, Pham KT, Salazar MG, Sun C, Grayson T, Decker JM, Wei X, Wang S, Goepfert PA, et al: Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 Infection. Proc Natl Acad Sci USA. 2008, 105: 7552-7557. 10.1073/pnas.0802203105.PubMed CentralView ArticlePubMed
- Gottlieb GS, Heath L, Nickle DC, Wong KG, Leach SE, Jacobs B, Gezahegne S, van 't Wout AB, Jacobson LP, Margolick JB, Mullins JI: HIV-1 variation before seroconversion in men who have sex with men: analysis of acute/early HIV infection in the multicenter AIDS cohort study. J Infect Dis. 2008, 197: 1011-1015. 10.1086/529206.PubMed CentralView ArticlePubMed
- Kuyl van der AC, Cornelissen M: Identifying HIV-1 dual infections. Retrovirology. 2007, 4: 67-10.1186/1742-4690-4-67.PubMed CentralView ArticlePubMed
- Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Grobler J, Li F, Liu SL, Rademeyer C, Learn GH, Karim SS, et al: Dual HIV-1 infection associated with rapid disease progression. Lancet. 2004, 363: 619-622. 10.1016/S0140-6736(04)15596-7.View ArticlePubMed
- Gottlieb GS, Nickle DC, Jensen MA, Wong KG, Kaslow RA, Shepherd JC, Margolick JB, Mullins JI: HIV type 1 superinfection with a dual-tropic virus and rapid progression to AIDS: a case report. Clin Infect Dis. 2007, 45: 501-509. 10.1086/520024.View ArticlePubMed
- Costa LJ, Mayer AJ, Busch MP, Diaz RS: Evidence for Selection of more Adapted Human Immunodeficiency Virus Type 1 Recombinant Strains in a Dually Infected Transfusion Recipient. Virus Genes. 2004, 28: 259-272. 10.1023/B:VIRU.0000025773.12621.a8.View ArticlePubMed
- Haigwood NL: Predictive value of primate models for AIDS. AIDS Rev. 2004, 6: 187-198.PubMed
- Hu SL: Non-human primate models for AIDS vaccine research. Curr Drug Targets Infect Disord. 2005, 5: 193-201. 10.2174/1568005054201508.PubMed CentralView ArticlePubMed
- Lackner AA, Veazey RS: Current concepts in AIDS pathogenesis: insights from the SIV/macaque model. Annu Rev Med. 2007, 58: 461-476. 10.1146/annurev.med.58.082405.094316.View ArticlePubMed
- Staprans SI, Dailey PJ, Rosenthal A, Horton C, Grant RM, Lerche N, Feinberg MB: Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection. J Virol. 1999, 73: 4829-4839.PubMed CentralPubMed
- Mellors JW, Kingsley LA, Rinaldo CR, Todd JA, Hoo BS, Kokka RP, Gupta P: Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med. 1995, 122: 573-579.View ArticlePubMed
- Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996, 272: 1167-1170. 10.1126/science.272.5265.1167.View ArticlePubMed
- Centlivre M, Sala M, Wain-Hobson S, Berkhout B: In HIV-1 pathogenesis the die is cast during primary infection. Aids. 2007, 21: 1-11. 10.1097/QAD.0b013e3280117f7f.View ArticlePubMed
- Overbaugh J, Bangham CR: Selection forces and constraints on retroviral sequence variation. Science. 2001, 292: 1106-1109. 10.1126/science.1059128.View ArticlePubMed
- Rybarczyk BJ, Montefiori D, Johnson PR, West A, Johnston RE, Swanstrom R: Correlation between env V1/V2 region diversification and neutralizing antibodies during primary infection by simian immunodeficiency virus sm in rhesus macaques. J Virol. 2004, 78: 3561-3571. 10.1128/JVI.78.7.3561-3571.2004.PubMed CentralView ArticlePubMed
- Allen TM, O'Connor DH, Jing P, Dzuris JL, Mothe BR, Vogel TU, Dunphy E, Liebl ME, Emerson C, Wilson N, et al: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature. 2000, 407: 386-390. 10.1038/35036559.View ArticlePubMed
- O'Connor DH, Allen TM, Vogel TU, Jing P, DeSouza IP, Dodds E, Dunphy EJ, Melsaether C, Mothe B, Yamamoto H, et al: Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection. Nat Med. 2002, 8: 493-499. 10.1038/nm0502-493.View ArticlePubMed
- Lichterfeld M, Yu XG, Cohen D, Addo MM, Malenfant J, Perkins B, Pae E, Johnston MN, Strick D, Allen TM, et al: HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS. 2004, 18: 1383-1392. 10.1097/01.aids.0000131329.51633.a3.View ArticlePubMed
- Ueno T, Motozono C, Dohki S, Mwimanzi P, Rauch S, Fackler OT, Oka S, Takiguchi M: CTL-mediated selective pressure influences dynamic evolution and pathogenic functions of HIV-1 Nef. J Immunol. 2008, 180: 1107-1116.View ArticlePubMed
- Huang KJ, Wooley DP: A new cell-based assay for measuring the forward mutation rate of HIV-1. J Virol Methods. 2005, 124: 95-104. 10.1016/j.jviromet.2004.11.010.View ArticlePubMed
- Kirchhoff F, Easterbrook PJ, Douglas N, Troop M, Greenough TC, Weber J, Carl S, Sullivan JL, Daniels RS: Sequence variations in human immunodeficiency virus type 1 Nef are associated with different stages of disease. J Virol. 1999, 73: 5497-5508.PubMed CentralPubMed
- Palmer S, Kearney M, Maldarelli F, Halvas EK, Bixby CJ, Bazmi H, Rock D, Falloon J, Davey RT, Dewar RL, et al: Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis. J Clin Microbiol. 2005, 43: 406-413. 10.1128/JCM.43.1.406-413.2005.PubMed CentralView ArticlePubMed
- Shriner D, Rodrigo AG, Nickle DC, Mullins JI: Pervasive genomic recombination of HIV-1 in vivo. Genetics. 2004, 167: 1573-1583. 10.1534/genetics.103.023382.PubMed CentralView ArticlePubMed
- Harris RS, Liddament MT: Retroviral restriction by APOBEC proteins. Nat Rev Immunol. 2004, 4: 868-877. 10.1038/nri1489.View ArticlePubMed
- Simon V, Zennou V, Murray D, Huang Y, Ho DD, Bieniasz PD: Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathog. 2005, 1: e6-10.1371/journal.ppat.0010006.PubMed CentralView ArticlePubMed
- Bourara K, Liegler TJ, Grant RM: Target cell APOBEC3C can induce limited G-to-A mutation in HIV-1. PLoS Pathog. 2007, 3: 1477-1485. 10.1371/journal.ppat.0030153.View ArticlePubMed
- Slatkin M, Hudson RR: Pairwise comparisons of mitochondrial DNA sequences in stable and exponentially growing populations. Genetics. 1991, 129: 555-562.PubMed CentralPubMed
- Smith JM, Haigh J: The hitch-hiking effect of a favourable gene. Genet Res. 1974, 23: 23-35.View ArticlePubMed
- Charlesworth D, Morgan MT, Charlesworth B: The effect of linkage and population size on inbreeding depression due to mutational load. Genet Res. 1992, 59: 49-61.View ArticlePubMed
- Miller MD, Warmerdam MT, Gaston I, Greene WC, Feinberg MB: The human immunodeficiency virus-1 nef gene product: a positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med. 1994, 179: 101-113. 10.1084/jem.179.1.101.View ArticlePubMed
- Sinclair E, Barbosa P, Feinberg MB: The nef gene products of both simian and human immunodeficiency viruses enhance virus infectivity and are functionally interchangeable. J Virol. 1997, 71: 3641-3651.PubMed CentralPubMed
- Arien KK, Verhasselt B: HIV Nef: role in pathogenesis and viral fitness. Curr HIV Res. 2008, 6: 200-208. 10.2174/157016208784325001.View ArticlePubMed
- Wakeley J: Coalescent Theory: An Introduction. 2008, Robert & Company Publishers
- Brown AJ: Analysis of HIV-1 env gene sequences reveals evidence for a low effective number in the viral population. Proc Natl Acad Sci USA. 1997, 94: 1862-1865. 10.1073/pnas.94.5.1862.PubMed CentralView ArticlePubMed
- Achaz G, Palmer S, Kearney M, Maldarelli F, Mellors JW, Coffin JM, Wakeley J: A robust measure of HIV-1 population turnover within chronically infected individuals. Mol Biol Evol. 2004, 21: 1902-1912. 10.1093/molbev/msh196.View ArticlePubMed
- Shriner D, Liu Y, Nickle DC, Mullins JI: Evolution of intrahost HIV-1 genetic diversity during chronic infection. Evolution. 2006, 60: 1165-1176.PubMed
- Rouzine IM, Coffin JM: Linkage disequilibrium test implies a large effective population number for HIV in vivo. Proc Natl Acad Sci USA. 1999, 96: 10758-10763. 10.1073/pnas.96.19.10758.PubMed CentralView ArticlePubMed
- Ronaghi M, Uhlen M, Nyren P: A sequencing method based on real-time pyrophosphate. Science. 1998, 281: 363-365. 10.1126/science.281.5375.363.View ArticlePubMed
- Kestler H, Kodama T, Ringler D, Marthas M, Pedersen N, Lackner A, Regier D, Sehgal P, Daniel M, King N, et al: Induction of AIDS in rhesus monkeys by molecularly cloned simian immunodeficiency virus. Science. 1990, 248: 1109-1112. 10.1126/science.2160735.View ArticlePubMed
- Stafford MA, Corey L, Cao Y, Daar ES, Ho DD, Perelson AS: Modeling plasma virus concentration during primary HIV infection. J Theor Biol. 2000, 203: 285-301. 10.1006/jtbi.2000.1076.View ArticlePubMed
- Mattapallil JJ, Douek DC, Hill B, Nishimura Y, Martin M, Roederer M: Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature. 2005, 434: 1093-1097. 10.1038/nature03501.View ArticlePubMed
- Nowak MA, Lloyd AL, Vasquez GM, Wiltrout TA, Wahl LM, Bischofberger N, Williams J, Kinter A, Fauci AS, Hirsch VM, Lifson JD: Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol. 1997, 71: 7518-7525.PubMed CentralPubMed
- Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD: HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science. 1996, 271: 1582-1586. 10.1126/science.271.5255.1582.View ArticlePubMed
- Markowitz M, Louie M, Hurley A, Sun E, Di Mascio M, Perelson AS, Ho DD: A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo. J Virol. 2003, 77: 5037-5038. 10.1128/JVI.77.8.5037-5038.2003.PubMed CentralView ArticlePubMed
- Mansky LM, Temin HM: Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J Virol. 1995, 69: 5087-5094.PubMed CentralPubMed
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.